When was 4E Therapeutics founded?

4E Therapeutics was founded in 2019 and raised its 1st funding round 2 years after it was founded.

Where is 4E Therapeutics located?

4E Therapeutics is headquartered in Austin, United States.

How many employees does 4E Therapeutics have?

As of Sep 30, 2026, the latest employee count at 4E Therapeutics is 4.

Is 4E Therapeutics a funded company?

4E Therapeutics is a funded company, having raised a total of $***** in its 1st and only funding round, a Seed round on Nov 12, 2021.

When was the latest funding round of 4E Therapeutics?

4E Therapeutics' latest funding was a $***** Seed round on Nov 12, 2021, with participation from 0 investor.

Where does 4E Therapeutics rank among its competitors?

4E Therapeutics ranks 31st amongst 330 active competitors, of which 83 are funded. It stands 10th in terms of total funding among its competitors. The most recent competitor to raise funding was Quince Therapeutics, which secured $187M in May, 2026.

Who are the top competitors of 4E Therapeutics?

4E Therapeutics' top competitors include argenx, Vor Biopharma and Heron Therapeutics. Among them, Quince Therapeutics secured the most recent funding round in May, 2026.

4E Therapeutics - 2026 Company Profile, Team, Funding & Competitors

Company Details

Developer of drugs for treating neuropathic pain. The company is developing a non-opioid approach for the treatment of neuropathic pain by a novel mode of action. The company has demonstrated proof-of-principle with a small molecule MNK inhibitor that has potent analgesic activity in multiple animal pain models.

Key Metrics

Founded Year

2019

Location

Austin, United States

Stage

Acquired

Total Funding

$1.89M in 1 round

Latest Funding Round

Seed, Nov 12, 2021, $*****

Ranked

31^st among 330 active competitors

Employee Count

4 as on Sep 30, 2026

Similar Companies

Heron Therapeutics & 280 more

Exit Details

Acquired by Lilly (Jun 16, 2026)

View 4E Therapeutics' full profile

4E Therapeutics is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Reports
4e Therapeutics, Inc. CIN: 834556016 , United States, Active		-	-	-

4E Therapeutics got acquired by Lilly on Jun 16, 2026.

Click here to take a look at 4E Therapeutics's acquisition in detail

4E Therapeutics has raised a total funding of $1.89M over 1 round.

Here is the list of recent funding rounds of 4E Therapeutics:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Nov 12, 2021	7710298	Seed	2382446	2032182	7696933	5863909

Access funding benchmarks and valuations. Sign up today!

View details of 4E Therapeutics's funding rounds and investors

The founders of 4E Therapeutics are Ted Price and Joe Price.

Here are the details of 4E Therapeutics' key team members:

Ted Price: Co-Founder of 4E Therapeutics and founder of 1 other company.
Joe Price: Co-Founder & President of 4E Therapeutics.
Contact Info: 2 email addresses

View details of 4E Therapeutics's Founder profiles and Board Members

4E Therapeutics' employee count trend

4E Therapeutics has 4 employees as of Sep 26. Here is 4E Therapeutics's employee count trend over the years:

Employee count trend for 4E Therapeutics

Uncover 4E Therapeutics' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of 4E Therapeutics include argenx, Vor Biopharma and Heron Therapeutics. Here is the list of Top 10 competitors of 4E Therapeutics, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	argenx 2008, Ghent (Belgium), Public	Developer of antibody-based drugs to treat autoimmune diseases and cancer	$61.9M	Life Sciences Partners, Seventure Partners ... & 21 others	75/100
2nd	Vor Biopharma 2019, Cambridge (United States), Public	Developer of therapeutics to treat acute myeloid leukemia	$152M	NEXTBio, Mingxin Capital & 10 others	68/100
3rd	Heron Therapeutics 1983, Redwood City (United States), Public	Pharmaceutical company focused on acute care and oncology with innovative therapies	-	Deep Track Capital, Rubric Capital & 9 others	63/100
4th	Radius Health 2003, Boston (United States), Acquired	Biopharmaceutical company focused on bone health and related therapeutic areas	$213M	MPM BioImpact, Wellcome & 14 others	63/100
5th	Xenon Pharmaceuticals 2000, Burnaby (Canada), Public	Developer of small molecule drugs against rare channelopathies	$85.7M	Fidelity Investments, Invesco & 14 others	62/100
6th	Collegium Pharma 2002, Canton (United States), Public	Developer of therapeutics for chronic pain management	$103M	Longitude Capital, Skyline Ventures & 9 others	62/100
7th	Horizon Therapeutics 2008, Dublin (Ireland), Acquired	Developer of drugs for treating rare and autoimmune diseases	$61.8M	Atlas Venture, Avoro Capital & 4 others	61/100
8th	Quince Therapeutics 2012, San Francisco (United States), Public	Developer of therapeutics for orthopedic diseases	$108M	Pfizer Venture Investments, Balyasny Asset Management ... & 27 others	60/100
9th	Latigo Biotherapeutics 2019, Thousand Oaks (United States), Public	Developer of non-opioid pain medicines for central nervous system	$322M	Foresite Capital, Qatar Investment Authority ... & 11 others	60/100
10th	Foresee Pharmaceuticals 2011, Taipei (Taiwan), Public	Developer of injectables and NCEs for cancer and chronic diseases	$32.5M	CDIB Capital Group, Vivo Capital & 4 others	59/100
31st	4E Therapeutics 2019, Austin (United States), Acquired	Developer of drugs for treating neuropathic pain	$1.89M	-	50/100